## Clinical Context: Treatment-Resistant Depression (TRD) vs. Dose Optimization This patient presents with **recurrent depressive symptoms after initial response**—a scenario distinct from primary treatment resistance. Key clinical features: - Initial response to sertraline 100 mg (8 months of good control) - Relapse after 4 weeks (not primary failure) - Normal medical workup (TSH, B12, folate, CBC) - Confirmed adherence ### Management Algorithm for Relapsed Depression ```mermaid flowchart TD A[Depressive relapse on SSRI]:::outcome --> B{Adequate dose?}:::decision B -->|No| C[Optimize dose first]:::action B -->|Yes| D{Adequate duration?}:::decision D -->|< 4 weeks| E[Continue, reassess at 4 weeks]:::action D -->|≥ 4 weeks| F[Consider augmentation or switch]:::action C --> G[Recheck at 4 weeks]:::action F --> H{Response?}:::decision H -->|Yes| I[Maintain]:::outcome H -->|No| J[Augmentation: Li, T3, or atypical AP]:::action ``` ### Why Dose Increase First? **Key Point:** Before switching agents or augmenting, the current SSRI dose should be optimized. Sertraline 100 mg is in the lower-to-mid therapeutic range; doses up to 200 mg daily are standard. **High-Yield:** The hierarchy for managing relapsed depression on an SSRI is: 1. **Optimize dose** of current agent (if subtherapeutic) 2. **Extend duration** (allow 4–6 weeks at optimized dose) 3. **Augment** (lithium, T3, atypical antipsychotic) if inadequate response 4. **Switch** to alternative SSRI or different class only after failed augmentation ### Rationale for Dose Increase | Step | Rationale | Evidence | |------|-----------|----------| | Increase sertraline to 150 mg | Current dose (100 mg) may be suboptimal for relapse prevention | Dose-response studies show efficacy up to 200 mg/day | | Reassess in 4 weeks | Allows time for pharmacokinetic steady-state and clinical response | Standard timeline for SSRI dose changes | | Avoid premature switching | SSRIs have similar efficacy; switching without dose optimization wastes time | Meta-analyses show no superiority of one SSRI over another | | Avoid premature augmentation | Augmentation is second-line, reserved for inadequate response at optimized doses | Increases polypharmacy, cost, and side-effect burden | **Clinical Pearl:** Relapse after initial response often reflects inadequate maintenance dosing or life-cycle factors (seasonal, stress-related). Dose optimization is the most parsimonious and evidence-based first step. **Mnemonic: DOSE-FIRST** — **D**ose optimization, **O**ptimize before switching, **S**econd-line augmentation, **E**xtend duration at new dose, **F**irst-line agents are interchangeable, **I**ncrease by 25–50 mg, **R**eassess in 4 weeks, **S**witch only after failed optimization, **T**ry augmentation next. ## Why Other Options Are Incorrect **Switch to fluoxetine:** SSRIs have equivalent efficacy for MDD. Switching without optimizing the current dose is premature and delays response. Fluoxetine offers no advantage over sertraline at this stage. **Add lithium carbonate:** Augmentation is appropriate for treatment-resistant depression (failure at optimized doses for ≥4 weeks), not for relapse on a suboptimal dose. Lithium requires blood level monitoring and is second-line. **Discontinue sertraline and initiate tricyclic:** Tricyclic antidepressants (TCAs) are not first-line and carry greater side-effect burden (anticholinergic, cardiac, orthostatic hypotension) compared to SSRIs. Switching classes without dose optimization is not evidence-based. [cite:APA Practice Guideline for Depression], [cite:Kaplan & Sadock's Synopsis of Psychiatry 11e Ch 6], [cite:Maudsley Guidelines 2023]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.